In fact, nearly 1 in 4 women are affected by obesity, a statistic that highlights how widespread this issue is and the complex struggles so many face on their journey toward health
Phase 3 TRIUMPH-4 (topline) In Lillys topline summary, the most common adverse events included nausea, diarrhoea, constipation and vomiting (typical of incretin-based therapies)
9 Thng tin chung SK: ang cp nht Nh sn xut: Novo Nordisk A/S-Thu S ng gi: Hp 1 bt tim 10 C ch tc dng 10.1 Dc lc hc Semaglutide l mt loi thuc thuc nhm cht ch vn GLP-1 (glucagon-like peptide-1 receptor agonist), c s dng trong iu tr bnh i tho ng type 2 v h tr gim cn
The key is using GLP-1s as part of a comprehensive approach that includes good nutrition and strength training, not as a standalone solution
This proposal doesnt change access for patients using an FDA-approved GLP-1 Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Saxenda or Victoza